Susan M Chang1, Hans Messersmith2, Manmeet Ahluwalia3, David Andrews4, Priscilla K Brastianos5, Laurie E Gaspar6, Na Tosha N Gatson7, Justin T Jordan5, Mustafa Khasraw8, Andrew B Lassman9, Julia Maues10, Maciej Mrugala11, Jeffrey Raizer12, David Schiff13, Glen Stevens, Ashley Sumrall14, Martin Van den Bent15, Michael A Vogelbaum3. 1. University of California San Francisco, San Francisco, CA, USA. 2. American Society of Clinical Oncology, Alexandria, VA, USA. 3. Cleveland Clinic, Cleveland, OH, USA. 4. Thomas Jefferson University, Philadelphia, PA, USA. 5. Massachusetts General Hospital, Boston, MA, USA. 6. University of Colorado School of Medicine, Denver, CO, USA. 7. Geisinger, Neuroscience & Cancer Institutes, Danville, PA, USA. 8. The University of Sydney, NSW, Australia. 9. Columbia University Irving Medical Center, New York, NY, USA. 10. Georgetown Breast Cancer Advocates, Washington, DC, USA. 11. Mayo Clinic Phoenix, Phoenix, AZ, USA. 12. Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. 13. University of Virginia Medical Center, Charlottesville, VA, USA. 14. Levine Cancer Institute, Charlotte, NC, USA. 15. Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Abstract
BACKGROUND: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines on the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: Two CNS Guidelines were reviewed for developmental rigor by methodologists and an independent multi-disciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The expert panel voted to endorse the two guidelines and ASCO and SNO independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS: The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based upon the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines, with minor alterations. CONCLUSIONS: Key recommendations include: prophylactic anti-epileptic drugs were not recommended for routine use; corticosteroids (specifically dexamethasone) were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases.
BACKGROUND: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines on the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: Two CNS Guidelines were reviewed for developmental rigor by methodologists and an independent multi-disciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The expert panel voted to endorse the two guidelines and ASCO and SNO independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS: The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based upon the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines, with minor alterations. CONCLUSIONS: Key recommendations include: prophylactic anti-epileptic drugs were not recommended for routine use; corticosteroids (specifically dexamethasone) were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases.
Authors: Timothy C Ryken; John S Kuo; Roshan S Prabhu; Jonathan H Sherman; Steven N Kalkanis; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Laurie E Gaspar; Roshan S Prabhu; Alia Hdeib; D Jay McCracken; George F Lasker; Michael W McDermott; Steven N Kalkanis; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Jonathan H Sherman; Simon S Lo; Tom Harrod; Alia Hdeib; Yiping Li; Timothy Ryken; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Brian V Nahed; Christopher Alvarez-Breckenridge; Priscilla K Brastianos; Helen Shih; Andrew Sloan; Mario Ammirati; John S Kuo; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Susan M Chang; Hans Messersmith; Manmeet Ahluwalia; David Andrews; Priscilla K Brastianos; Laurie E Gaspar; Na Tosha N Gatson; Justin T Jordan; Mustafa Khasraw; Andrew B Lassman; Julia Maues; Maciej Mrugala; Jeffrey Raizer; David Schiff; Glen Stevens; Ashley Sumrall; Martin van den Bent; Michael A Vogelbaum Journal: J Clin Oncol Date: 2019-03-18 Impact factor: 44.544
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Pim B van der Meer; Linda Dirven; Martin J van den Bent; Matthias Preusser; Martin J B Taphoorn; Roberta Rudá; Johan A F Koekkoek Journal: Neurooncol Pract Date: 2021-10-21
Authors: Sung Kwon Kim; Jangsup Moon; Jin Mo Cho; Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Kyung Hwan Kim; Se Hoon Kim; Young Il Kim; Young Zoon Kim; Ho Sung Kim; Yun Sik Dho; Jae Sung Park; Ji Eun Park; Youngbeom Seo; Kyoung Su Sung; Jin Ho Song; Chan Woo Wee; Wan Soo Yoon; Hong In Yoon; Se Hoon Lee; Do Hoon Lim; Jung Ho Im; Jong Hee Chang; Myung Hoon Han; Je Beom Hong; Kihwan Hwang Journal: Brain Tumor Res Treat Date: 2020-04